Jacques Dumas appointed chairman of supervisory board, joined by new members Laurent Fraisse, Sandra Dubos and Martin Lauriot Prevost
Lyon, France, July 11, 2022 – Nosopharm, specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, today announces several changes to its supervisory board: Jacques Dumas has been appointed as chairman, taking over from Jacques Biton. Laurent Fraisse is replacing Marie-Paule Richard as an independent member and Sandra Dubos joins as the representative of investor Kreaxi, replacing Gwenael Hamon. Martin Lauriot Prevost joins as an historical investor.
These appointments will help Nosopharm to establish new strategic partnerships with both public and private companies, to carry out further development of its lead program, NOSO502, up to Phase 1 clinical studies, and to prepare its next round of financing. The company recently announced the completion and positive results of its preclinical toxicology studies for NOSO-502, a first-in-class antibiotic for the treatment of multidrug-resistant hospitalacquired infections.